DLPIC
ACAD icon

Davide Leone & Partners Investment Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,316
Closed -$447K – 60
2021
Q1 		$447K Buy
+17,316
New +$762K 0.06% 99

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Davide Leone & Partners Investment Company's ACAD Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 17,316 shares — an estimated $447K sold.

Davide Leone & Partners Investment Company first reported a position in ACAD in Q1 2021 and held it in 1 quarter. The position peaked at $447K in Q1 2021. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 17,316 Acadia Pharmaceuticals shares in Q2 2021, an estimated $447K.
  • Davide Leone & Partners Investment Company first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Davide Leone & Partners Investment Company's Acadia Pharmaceuticals position peaked at $447K in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.